CD4 T cell dysfunction and reprogramming during sepsis
脓毒症期间 CD4 T 细胞功能障碍和重编程
基本信息
- 批准号:10400169
- 负责人:
- 金额:$ 38.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-01 至 2026-04-30
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAcuteAddressAdultAffectAmericanAreaBackCD4 Positive T LymphocytesCause of DeathCell CompartmentationCellsCellular ImmunityCellular biologyCessation of lifeChildhoodChronicExposure toFunctional disorderFutureGenomicsGoalsHealthcare IndustryHumanHuman BiologyImmuneImmune responseImmune systemImmunosuppressionImpairmentIncidenceInfectionInterferon Type IIInterleukin-1 betaInterleukin-6InterventionInvestigationKnowledgeLaboratory miceLifeModelingMolecularMusNosocomial InfectionsOrganPatientsPhasePlayPopulationProteomicsRegulatory T-LymphocyteReportingResearchSamplingSecondary toSepsisSurvivorsTNF geneTimeTrainingcohortcostcytokinecytokine release syndromeemerging pathogenfitnessgut microbiotaimmune functionmetabolomicsmortalitymouse modelnovelpathogenpre-clinicalpreclinical studyresponsesecondary infectionseptic patients
项目摘要
Sepsis remains a major cause of death worldwide (11 million sepsis-related deaths were reported in 2017),
and that costs associated with treating septic patients place a large burden on the healthcare industry. Sepsis
is a life-threatening organ dysfunction caused by a dysregulated host response to infection. Early stages of
sepsis are marked by hyperinflammation driven by proinflammatory cytokines (i.e., IL-1β, IL-6, IFNγ, and TNF).
Patients who survive the acute phase of sepsis display long-term impairments in immune function. This state of
chronic immunoparalysis renders sepsis survivors increasingly susceptible to secondary infections.
Consequently, there is a desperate need to better understand the cellular and molecular basis of acute sepsis
pathophysiology and subsequent immune reprogramming that defines the prolonged immune suppression.
CD4 T cells, essential for coordinating the cellular and humoral immune response to a range of pathogens
under normal circumstances, are severely depleted during the acute stage of sepsis. The overall number of
CD4 T cells gradually recover over time, but their functional capacity remains blunted for many months. For the
past 10 years, we have focused our research to pursue the long-term goal of understanding how sepsis
impacts the CD4 T cell compartment because of the key role played by CD4 T cells in the overall fitness of the
immune system. We will continue our investigation of the cellular and molecular reprogramming of CD4 T cells
during sepsis in three interconnected areas of future research: 1) Define the mechanism(s) by which regulatory
CD4 T (Treg) cells expand during sepsis; 2) Perform an integrated discovery approach using genomics,
proteomics, and metabolomics to elucidate the molecular basis of sepsis pathophysiology and CD4 T cell
immunoparalysis; and 3) Determine how intestinal microbiota dysfunction during sepsis affects the magnitude
of the cytokine storm and promotes CD4 T cell immunoparalysis and increased incidence of late-onset
mortality. We will interrogate samples obtained from multiple cohorts of sepsis patients, as well as from
preclinical mouse models of sepsis at the level of Ag-specific CD4 T cell populations. Our preclinical studies
will be further strengthened by using a novel mouse model that mimics a critical aspect of human biology –
exposure to multiple ongoing and resolved infections trains the immune system for robust responses to new
pathogens – and will serve as an important and novel ‘transitional translational’ preclinical bridge between
humans and SPF laboratory mice to mechanistically study CD4 T cell dysfunction and reprogramming during
sepsis. Addressing these key gaps in knowledge regarding the effect of sepsis on CD4 T cell biology will likely
reveal new points of intervention that can be exploited in the future to restore CD4 T cell-mediated immunity,
and overall immune fitness, following sepsis.
脓毒症仍然是全世界的主要死亡原因(2017年报告了1100万例与败血症有关的死亡),
与治疗败血症患者相关的成本给医疗行业带来了巨大的负担。脓毒症
是一种威胁生命的器官功能障碍,由宿主对感染的失调反应引起。早期阶段
脓毒症的特征是由促炎细胞因子(即IL-1β、IL-6、干扰素γ和肿瘤坏死因子)驱动的炎症反应。
在脓毒症急性期幸存下来的患者表现出长期的免疫功能损害。这种状态
慢性免疫麻痹使败血症幸存者越来越容易受到继发感染。
因此,迫切需要更好地了解急性脓毒症的细胞和分子基础。
病理生理学和随后的免疫重新编程,定义了长期的免疫抑制。
CD4T细胞,对协调对一系列病原体的细胞和体液免疫反应至关重要
在正常情况下,在脓毒症的急性期严重耗尽。总人数
随着时间的推移,CD4T细胞逐渐恢复,但其功能能力在数月内仍然迟钝。对于
在过去的10年里,我们的研究重点是追求了解脓毒症如何发生的长期目标。
影响CD4T细胞隔间,因为CD4T细胞在机体整体健康状况中起着关键作用
免疫系统。我们将继续研究CD4T细胞的细胞和分子重编程
脓毒症期间三个相互关联的领域的未来研究:1)确定机制(S),通过
CD4T(Treg)细胞在脓毒症期间扩张;2)使用基因组学进行综合发现方法,
蛋白质组学和代谢组学阐明脓毒症病理生理学和CD4T细胞的分子基础
免疫麻痹;以及3)确定脓毒症期间肠道微生物区系功能障碍如何影响程度
细胞因子风暴和促进CD4T细胞免疫麻痹和增加晚发性发病率
死亡率。我们将询问从多个败血症患者队列中获得的样本,以及从
在抗原特异性CD4T细胞水平上的临床前脓毒症小鼠模型。我们的临床前研究
通过使用一种新的小鼠模型来模拟人类生物学的一个关键方面,将进一步加强-
暴露在多种持续和已解决的感染中,训练免疫系统对新的
病原体--并将成为一座重要而新颖的临床前过渡桥梁
人类和SPF实验室小鼠机械研究CD4T细胞功能障碍和重新编程
败血症。解决关于脓毒症对CD4T细胞生物学影响的知识中的这些关键差距可能会
揭示了未来可用于恢复CD4T细胞介导的免疫的新的干预点,
以及败血症后的整体免疫状况。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Thomas S Griffith其他文献
Apoptosis-inducing Ligand Cell-mediated Delivery of Tumor Necrosis Factor-related Induction of Glioblastoma Apoptosis Using Neural Stem Updated Version Cited Articles Citing Articles E-mail Alerts Induction of Glioblastoma Apoptosis Using Neural Stem Cell-mediated Delivery of Tumor Necrosis Factor-r
细胞凋亡诱导配体 细胞介导的肿瘤坏死因子相关传递 使用神经干诱导胶质母细胞瘤细胞凋亡 更新版本 被引文章 引用文章 电子邮件提醒 使用神经干细胞介导的肿瘤坏死因子-r 诱导胶质母细胞瘤凋亡
- DOI:
- 发表时间:
2013 - 期刊:
- 影响因子:0
- 作者:
Moneeb Ehtesham;P. Kabos;M. Gutierrez;N. Chung;Thomas S Griffith;Keith L. Black;John S. Yu - 通讯作者:
John S. Yu
EARLY MICRORECANALIZATION OF VAS DEFERENS AFTER IMPLANTATION OF BIODEGRADABLE GRAFTS IN RATS THAT PREVIOUSLY UNDERWENT BILATERAL VASECTOMY
- DOI:
10.1016/s0022-5347(08)61866-2 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Christopher M Simons;Barry R De Young;Thomas S Griffith;Timothy L Ratliff;Surya K Mallapragada;Moshe Wald - 通讯作者:
Moshe Wald
ACTIVATION OF TUMOR-SPECIFIC CD8+ T CELLS AFTER INTRATUMORAL Ad5-TRAIL/CpG ODN COMBINATION THERAPY
- DOI:
10.1016/s0022-5347(08)60117-2 - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Rebecca L VanOosten;Thomas S Griffith - 通讯作者:
Thomas S Griffith
PHASE I TRIAL OF Ad5-TRAIL-MEDIATED GENE TRANSFER IN MEN WITH LOCALLY-CONFINED PROSTATE CANCER PRIOR TO PLANNED RADICAL PROSTATECTOMY
- DOI:
10.1016/s0022-5347(08)61160-x - 发表时间:
2008-04-01 - 期刊:
- 影响因子:
- 作者:
Thomas S Griffith;Badrinath R Konety;Fadi N Joudi;Tammy Madsen;Barbara Ziegler;Michael B Cohen;Timothy L Ratliff;Richard D Williams - 通讯作者:
Richard D Williams
Thomas S Griffith的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Thomas S Griffith', 18)}}的其他基金
BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
- 批准号:
10582394 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
综合使用基因组学、代谢组学和细胞因子分析来验证使用“脏”小鼠研究脓毒症病理生理学
- 批准号:
10257687 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
CD4 T cell dysfunction and reprogramming during sepsis
脓毒症期间 CD4 T 细胞功能障碍和重编程
- 批准号:
10633073 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
利用微生物暴露研究对尿路致病性大肠杆菌的免疫反应
- 批准号:
10413143 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Integrated use of genomics, metabolomics, and cytokine profiling to validate the use of 'dirty' mice to study sepsis pathophysiology
综合使用基因组学、代谢组学和细胞因子分析来验证使用“脏”小鼠研究脓毒症病理生理学
- 批准号:
10512750 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Exploiting microbial exposure to study the immune response to uropathogenic E. coli
利用微生物暴露研究对尿路致病性大肠杆菌的免疫反应
- 批准号:
10237569 - 财政年份:2021
- 资助金额:
$ 38.75万 - 项目类别:
Impairment and recovery of CD4 T cell-dependent B cell responses after sepsis
脓毒症后 CD4 T 细胞依赖性 B 细胞反应的受损和恢复
- 批准号:
10084212 - 财政年份:2012
- 资助金额:
$ 38.75万 - 项目类别:
相似海外基金
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 38.75万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
- 批准号:
484000 - 财政年份:2023
- 资助金额:
$ 38.75万 - 项目类别:
Operating Grants














{{item.name}}会员




